Journal of Primeasia
Integrative Disciplinary Research | Online ISSN 3064-9870
  1. You are here:
  2. Home
  3. Journals
  4. Biological Sciences
RESEARCH ARTICLE   (Open Access)
Contents Vol 6 (1)

The Influence of Chronic Kidney Disease on Hepatocellular Carcinoma

Shib Shankar Das1, Md. Shamim Hossain2, Afrin Sultana3, Faisal Akter Rana4, Amzad Hossen5, Md. Sakibul Maowla6, Md. Khaja Mohi Uddin7, Md. Abu Sayem 8, Moazzam Hossian 9, Md Samiul Bashir 10*

+ Author Affiliations

Journal of Primeasia 6 (1) 1-8 https://doi.org/10.25163/primeasia.6110204

Submitted: 03 February 2025 Revised: 10 April 2025  Published: 14 April 2025 

Abstract

Background: This study looks at the stages of CKD in conjunction with the risk markers AFP, liver enzymes ALT and AST, and platelet count as they appear in 400 HCC patients categorized based on their renal function. According to recent findings, the accumulation of inflammatory uremic toxins may make renal failure a risk factor for the quicker progression of HCC. Methods: The patients were grouped by renal functions as follows: baseline (creatinine < 1.2 mg/dL signifying normal, n=250) and CKD patients (n=150 with creatinine ≥ 1.2 mg/dL). Severe CKD was defined as greater than 5 mg/dL (n=15). All patients assessed by capture of all possible lab inflammatory markers including C-reactive protein for comprehensive ruling out of confounding factors. Results: Severe CKD demonstrated substantially higher AFP levels than normal kidney function (402.3 vs 98.2 ng/mL, p<0.001) and a strong positive correlation between creatinine and AFP (r=0.62, R²=38.4%). For instance, ALT rose by 66%, while AST increased by 54% in severe CKD leading to significant elevation of liver injury markers (p<0.05). Platelet counts were reduced by 28% in severe CKD indicating the possibility for portal hypertension (p<0.001). Conclusion: The data from this study suggest that CKD leads to significant changes in HCC risk related markers, possibly by means of systemic metabolic disturbances and inflammation. Therefore, it is important to monitor simultaneously both kidney and liver functions in patients with HCC, especially those with an advanced form of CKD which will reveal the symptoms at an early stage and help to better manage them.Keyword: Chronic Kidney Disease, Hepatocellular Carcinoma, AFP diagnostic, Inflammatory Markers.

References

Agidew, M. M., Abebe, E. C., Muche, Z. T., Mengstie, M. A., Mulu, A. T., Admasu, F. T., ... & Dejenie, T. A. (2023). Evaluation of liver function biomarkers, blood pressure, and anthropometric parameters among chronic kidney disease patients: Laboratory-based cross-sectional study in Northwest Ethiopia. Metabolism Open, 19, 100254.

Ahn, J. C., Lee, Y., Agopian, V. G., Zhu, Y., You, S., Tseng, H., & Yang, J. D. (2022). Hepatocellular carcinoma surveillance: current practice and future directions. Hepatoma Research. https://doi.org/10.20517/2394-5079.2021.131

Almaguer, M., Herrera, R., & Orantes, C. M. (2014). Chronic kidney disease of unknown etiology in agricultural communities. MEDICC review, 16(2), 09-15.

Armstrong, D., Kline-Rogers, E., Jani, S. M., Goldman, E. B., Fang, J., Mukherjee, D., Nallamothu, B. K., & Eagle, K. A. (2005). Potential impact of the HIPAA privacy rule on data collection in a registry of patients with acute coronary Syndrome. Archives of Internal Medicine, 165(10), 1125. https://doi.org/10.1001/archinte.165.10.1125

Chanda, M., Biswas, T., Roy, M. N., Sampa, S. R., Saha, P., Sharna, R. J., ... & Rahman, M. A. (2021). Association of Liver Enzymes and Lipid Profile in Adults at Tertiary Level Hospitalin Bangladesh. J Natl Inst Lab Med Ref Bangladesh, 1(1), 17-24.

Cullaro, G., Kanduri, S. R., & Velez, J. C. Q. (2022). Acute Kidney Injury in Patients with Liver Disease. Clinical Journal of the American Society of Nephrology, 17(11), 1674–1684. https://doi.org/10.2215/cjn.03040322

Dekkers, I., De Mutsert, R., De Vries, A., Rosendaal, Cannegieter, S., Jukema, J., Cessie, S. L., Rabelink, T., Lamb, H., & Lijfering, W. (2017). Determinants of impaired renal and vascular function are associated with elevated levels of procoagulant factors in the general population. Journal of Thrombosis and Haemostasis, 16(3), 519–528. https://doi.org/10.1111/jth.13935

Elsayed, M. O. K. (2023). Hepatocellular carcinoma surveillance in cirrhotic patients: Beyond guidelines. Gastroenterology and Functional Medicine, 1(1). https://doi.org/10.54844/gfm.2023.439

Hamilton, C. M., Strader, L. C., Pratt, J. G., Maiese, D., Hendershot, T., Kwok, R. K., Hammond, J. A., Huggins, W., Jackman, D., Pan, H., Nettles, D. S., Beaty, T. H., Farrer, L. A., Kraft, P., Marazita, M. L., Ordovas, J. M., Pato, C. N., Spitz, M. R., Wagener, D., . . . Haines, J. (2011). The PhenX toolkit: Get the most from your measures. American Journal of Epidemiology, 174(3), 253–260. https://doi.org/10.1093/aje/kwr193

https://doi.org/10.25163/primeasia.519787

Hussain, J., Grubic, N., Akbari, A., Canney, M., Elliott, M. J., Ravani, P., Tanuseputro, P., Clark, E. G., Hundemer, G. L., Ramsay, T., Tangri, N., Knoll, G. A., & Sood, M. M. (2023). Associations between modest reductions in kidney function and adverse outcomes in young adults: retrospective, population based cohort study. BMJ, e075062. https://doi.org/10.1136/bmj-2023-075062

Islam, M. R., Yesmin, T., Prapty, A. N., Biswash, M. A. R., Rana, M. S., & Rashid, M. H. O. (2024). Natural environmental sources of resveratrol and its therapeutic role in cancer prevention. Australian Herbal Insight, 7(1), 1-11. https://doi.org/10.25163/ahi.719931

Jagdish, R. K., Roy, A., Kumar, K., Premkumar, M., Sharma, M., Rao, P. N., Reddy, D. N., & Kulkarni, A. V. (2023). Pathophysiology and management of liver cirrhosis: from portal hypertension to acute-on-chronic liver failure. Frontiers in Medicine, 10. https://doi.org/10.3389/fmed.2023.1060073

Kanubhai, D. M., & Sabirali, S. M. (2023). Hepatocellular carcinoma: a review. Asian Journal of Research in Pharmaceutical Sciences, 171–179. https://doi.org/10.52711/2231-5659.2023.00030

Kleber, M., Ihorst, G., Deschler, B., Jakob, C., Liebisch, P., Koch, B., Sezer, O., & Engelhardt, M. (2009). Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. European Journal of Haematology, 83(6), 519–527. https://doi.org/10.1111/j.1600-0609.2009.01318.x

Kubota, N., Fujiwara, N., & Hoshida, Y. (2020). Clinical and molecular prediction of hepatocellular carcinoma risk. Journal of Clinical Medicine, 9(12), 3843. https://doi.org/10.3390/jcm9123843

Kuster, N., Cristol, J., Cavalier, E., Bargnoux, A., Halimi, J., Froissart, M., Piéroni, L., & Delanaye, P. (2013). Enzymatic creatinine assays allow estimation of glomerular filtration rate in stages 1 and 2 chronic kidney disease using CKD-EPI equation. Clinica Chimica Acta, 428, 89–95. https://doi.org/10.1016/j.cca.2013.11.002 Eckardt, K., & Kasiske, B. L. (2012). KDIGO Clinical Practice Guideline for Glomerulonephritis. https://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25868939

Lee, C. (2013). Hepatocellular carcinoma in patients with chronic kidney disease. World Journal of Gastroenterology, 19(16), 2466. https://doi.org/10.3748/wjg.v19.i16.2466

Lisboa, U. De. (2021). Targeting liver cell metabolism and function in non-alcoholic fatty liver disease.

Md Tahsin Salam, Moushumi Afroza Mou et al. (2024). Assessment of Lipid Profile in Hepatocellular Carcinoma Patients: A Prospective Study in Bangladesh, Journal of Primeasia, 5(1), 1–8, 9787.

Neugarten, J., & Golestaneh, L. (2019). Liver disease and chronic kidney disease. In Elsevier eBooks (pp. 863–882). https://doi.org/10.1016/b978-0-12-815876-0.00053-x

Nourie, N., Ghaleb, R., Lefaucheur, C., & Louis, K. (2024). Toward precision Medicine: Exploring the landscape of biomarkers in acute kidney injury. Biomolecules, 14(1), 82. https://doi.org/10.3390/biom14010082

Poropat, G. (2024). FROM ORIGINS TO OUTCOMES: INVESTIGATING THE COMPLEXITY OF PORTAL HYPERTENSION IN ETIOLOGY, DIAGNOSIS, TREATMENT AND COMPLICATIONS. https://zir.nsk.hr/islandora/object/medri:8807

Rana, M. S., Bashir, M. S., Das, S. S., Hossain, M., & Barua, S. (2024). Biomarkers for hepatocellular carcinoma: Diagnosis, prognosis, and treatment response assessment – A systematic review. Journal of Primeasia, 5(1), 1–8. https://doi.org/10.25163/primeasia.519784

Sahu, N., Rakshit, S., & Bhaskar, L. (2022). Risk factors and pathogenic mechanism–associated hepatocellular carcinoma. In Elsevier eBooks (pp. 33–49). https://doi.org/10.1016/b978-0-323-98806-3.00023-4

Salam, M. T., Mou, M. A., Bari, K. F., Roy, N. C., Al-Mamun, A., Ullah, M. S., Hussen, M. A., Rana, M. S., & Hossain, M. B. (2025). Assessment of lipid profile in hepatocellular carcinoma patients: A prospective study in Bangladesh. Journal of Primeasia, 5(1), 1–8. https://doi.org/10.25163/primeasia.519787

Septiarini, N. N. A., Wardhani, N. P., Maimunah, N. U., & Indrasari, N. Y. N. (2024). Demographics, risk factors, clinical manifestations, staging and liver function tests of hepatocellular Carcinoma: A literature review. World Journal of Advanced Research and Reviews, 24(3), 2087–2093. https://doi.org/10.30574/wjarr.2024.24.3.3853

Song, P., Tang, Q., Feng, X., & Tang, W. (2016). Biomarkers: evaluation of clinical utility in surveillance and early diagnosis for hepatocellular carcinoma. Scandinavian Journal of Clinical and Laboratory Investigation, 76(sup245), S70–S76. https://doi.org/10.1080/00365513.2016.1210328

Suraweera, D., Konyn, P., Vu, T., & Saab, S. (2018). Clinical epidemiology of chronic liver disease: Hepatocellular carcinoma. In Springer eBooks (pp. 229–249). https://doi.org/10.1007/978-3-319-94355-8_15

Thomas, M. E., Blaine, C., Dawnay, A., Devonald, M. A., Ftouh, S., Laing, C., Latchem, S., Lewington, A., Milford, D. V., & Ostermann, M. (2014). The definition of acute kidney injury and its use in practice. Kidney International, 87(1), 62–73. https://doi.org/10.1038/ki.2014.328

Tufael, M., Kar, A., Rashid, M. H. O., Sunny, A. R., Raposo, A., Islam, M. S., Hussain, M. A., Hussen, M. A., Han, H., Coutinho, H. D. M., Ullah, M. S., & Rahman, M. M. (2024). Diagnostic efficacy of tumor markers AFP, CA19-9, and CEA in hepatocellular carcinoma patients.Journal of Angiotherapy, 8(4), 1-10. https://doi.org/10.25163/angiotherapy.849513

Tufael, M., Kar, A., Upadhye, V. J., Dutta, A., Islam, M. R., Sattar, A., Ali, M. E., Akter, J., Bari, K. F., Salam, M. T., Banik, P. C., Khan, M. S. S., & Sunny, A. R. (2024). Significance of serum biomarkers in early diagnosis of hepatocellular carcinoma in patients with Fisher groups. Journal of Angiotherapy, 8(1), 1-9.https://doi.org/10.25163/angiotherapy.819440

Tufael, M., Rahman, M. M., Upadhye, V. J., Hossain, M. F., & Uddin, N. (2024). Combined biomarkers for early diagnosis of hepatocellular carcinoma. Journal of Angiotherapy, 8(5), 1-12. https://doi.org/10.25163/angiotherapy.859665

World Medical Association Declaration of Helsinki. (2024). JAMA. https://doi.org/10.1001/jama.2024.21972

Abstract
Export Citation

View Dimensions


View Plumx


View Altmetric



0
Save
0
Citation
21
View
0
Share